Solomon Moshkevich Sells 6,000 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 6,000 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $143.29, for a total value of $859,740.00. Following the completion of the sale, the insider now owns 143,768 shares in the company, valued at $20,600,516.72. The trade was a 4.01 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, January 29th, Solomon Moshkevich sold 5,201 shares of Natera stock. The shares were sold at an average price of $165.87, for a total value of $862,689.87.
• On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,101,319.17.
• On Monday, December 9th, Solomon Moshkevich sold 4,858 shares of Natera stock. The shares were sold at an average price of $166.59, for a total transaction of $809,294.22.

Natera Price Performance

Natera stock opened at $140.66 on Monday. The company’s 50 day moving average is $165.61 and its two-hundred day moving average is $148.09. The firm has a market cap of $19.02 billion, a PE ratio of -79.92 and a beta of 1.80. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 52-week low of $83.13 and a 52-week high of $183.00.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. On average, research analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analysts Set New Price Targets

NTRA has been the subject of a number of recent analyst reports. Piper Sandler lifted their price objective on shares of Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Tuesday, March 4th. Morgan Stanley upped their price target on Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. TD Cowen raised their price objective on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. The Goldman Sachs Group boosted their target price on shares of Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th. Finally, Guggenheim raised their target price on Natera from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $173.56.

Hedge Funds Weigh In On Natera

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. LRI Investments LLC purchased a new stake in shares of Natera in the 4th quarter valued at approximately $29,000. Blue Trust Inc. raised its stake in Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after buying an additional 97 shares in the last quarter. Versant Capital Management Inc lifted its stake in Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after purchasing an additional 166 shares during the last quarter. Covestor Ltd boosted its holdings in Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 95 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock valued at $52,000 after purchasing an additional 261 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.